BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback